Breaking Finance News

Idera Pharmaceuticals Up 14 Percent Monday- Why? (IDRA)

7544735974_1c5eb77371_zShares of Idera Pharmaceuticals,  (NASDAQ: IDRA) are up more than 14 percent Monday after the company announced second quarter earnings that pleased the street.

 Have you signed up for our mailing list? No SPAM. We promise! Look to the right —>

 

The company reported a second-quarter EPS loss of $(0.15) versus the estimated loss of $(0.12), missing by $0.03 but higher by 57 percent year over year. More bullish to investors, Idera also announced that it had $16.3 million in cash that would allow it to complete Phase 2 trials of IMO-8400. On July 1, we reported the positive results of Phase 1 trials of IMO-8400 that sent the stock higher. (Read that story here)

Also reported were positive data from IMO-3100 for patients with moderate-to-severe plaque psoriasis. The phase 2 trial revealed that it was well tolerated and showed up to a 90 percent improvement from the baseline.

Over the past three months, investors have bid the stock up more than 120 percent on a continuous string of positive data and the idea that the $78 million company with a promising pipeline is a prime takeover target.

Company Profile:

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its autoimmune and inflammatory disease programs include IMO-3100, an antagonist of TLR7 and TLR9, which has completed Phase II clinical trials for the treatment of psoriasis; and IMO-8400, an antagonist of TLR7, TLR8, and TLR9 that is in Phase I clinical trials for the treatment of psoriasis/lupus. (read more at Yahoo! Finance)

[stock-tools exchange="NASDAQ" symbol="GLD" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

New to Breaking Finance News? Read about our format here.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.